Cronos Group Inc. filings document operating results, governance matters, capital structure and material events for a British Columbia-based cannabis issuer. Form 8-K reports include financial-results releases, material agreements, regulatory disclosures, capital-structure items and changes involving finance leadership or principal accounting responsibilities.
Proxy and shareholder-meeting filings describe director elections, executive compensation votes, auditor appointments, board governance and voting results. The filing record also reflects the company’s public-company reporting framework for its cannabis brand portfolio, including Spinach®, PEACE NATURALS®, LIT® and Lord Jones®, and the governance disclosures associated with its common shares listed under CRON.
Cronos Group Inc. General Manager Christopher Martens received a grant of 46,875 restricted stock units (RSUs) on October 16, 2026. Each RSU represents a contingent right to receive one common share, and the units vest in three substantially equal installments beginning on the first anniversary of the grant date. The reported direct RSU position following the grant was 46,875.
Cronos Group Inc. (CRON) completed its acquisition of all issued and outstanding shares of CanAdelaar B.V. on October 15, 2026, making it a wholly owned subsidiary. The stated base purchase price was €57.5 million, subject to closing and post-closing adjustments. Additional cash consideration may become payable in amounts equal to 50% of CanAdelaar’s Normalised EBITDA for each of 2026 and 2027.
CanAdelaar operates a 540,000-square-foot greenhouse and supplies nearly all 69 coffee shops in the Dutch Wietexperiment, a regulated pilot across ten municipalities with ten licensed producers.
CanAdelaar’s results annualized from the six months ended June 30, 2026 were net revenue of €41.6 million and Adjusted EBITDA of €20.1 million; Adjusted EBITDA was €24.2 million for the 12 months ended September 30, 2025. The stated decline primarily reflected increased competition as the Wietexperiment became fully operational. These annualized figures are not actual full-year results or forecasts; the underlying figures were unaudited and prepared under Dutch GAAP, and Adjusted EBITDA is a non-GAAP measure.
Cronos Group Inc. (symbol: CRON) is the issuer of record for a Form 8-K filing submitted to the SEC.
Garnick Murray R reported acquisition or exercise transactions in this Form 4 filing.
Cronos Group Inc. director Murray R. Garnick reported a grant of 48,859.93 Deferred Share Units on August 6, 2026. Each unit provides a cash payment equal to the fair market value of Cronos common shares at redemption. Following this award, he holds 179,594.40 Deferred Share Units, which are mandatorily redeemed in cash after he ceases to be a director.
RUDYK JAMES DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Cronos Group Inc. director James Daniel Rudyk received a grant of 48,859.9300 Deferred Share Units (DSUs) on August 6, 2026. Following this award, he holds 362,742.2200 DSUs directly. Each DSU entitles him, upon redemption, to a lump-sum cash payment equal to the fair market value of a Cronos common share on the redemption date, and vested DSUs are mandatorily redeemed on the first trading day after he ceases to be a director.
ADLER JASON MARC reported acquisition or exercise transactions in this Form 4 filing.
Cronos Group Inc. director Jason Marc Adler received a grant of 48,859.9300 Deferred Share Units, each linked to an equal number of common shares for valuation purposes. After this grant, he holds 362,742.2200 Deferred Share Units, which will be redeemed for a lump-sum cash payment based on the fair market value of Cronos Group common shares after he ceases to be a director.
Cronos Group Inc. adopted an annual schedule for shareholder Say-on-Pay Votes on executive compensation. At the 2026 Annual Meeting of Shareholders held on June 18, 2026, investors indicated a preference for annual votes. The board has now decided to follow that preference until the next required Say-on-Frequency Vote.
Cronos Group Inc., a global cannabis company, reported markedly stronger Q2 2026 results. Net revenue was $53,007 versus $33,455 a year earlier, with gross profit of $28,451 and operating income of $7,404 versus a prior operating loss. Net income attributable to Cronos Group was $32,085 compared with a loss in Q2 2025, helped by higher cannabis flower and extract sales and a foreign currency gain of $20,219.
For the first six months of 2026, net revenue rose to $98,217 and operating income to $5,571, with Adjusted EBITDA improving to $18,167 from $3,977. Q2 Adjusted EBITDA reached $13,088, while restructuring costs fell to $308. Canada and Israel remained the largest markets.
Liquidity stayed very strong: cash and cash equivalents, short-term investments and non‑current interest-bearing deposits totaled $827,019 against total liabilities of $62,415 as of June 30, 2026. The company repurchased 12,253,870 shares for $32,858 year‑to‑date and authorized a new share repurchase program of up to $50,000, with open‑market buybacks capped at 18,712,918 shares. A proposed $10,000,000 settlement of a U.S. securities class action is pending final court approval, and new anti‑dumping investigations in Israel could affect future imports. Two major customers accounted for 44% of Q2 net revenue before excise taxes.
Cronos Group Inc. reported a record second quarter for the period ended June 30, 2026, with net revenue of $53.0 million, up 58% year-over-year, and gross profit of $28.5 million, up 96%. Gross margin expanded to 54%, reflecting a mix shift toward Israel and other export markets that are not subject to excise taxes, along with higher sales volumes.
The company generated net income of $35.7 million, compared to a net loss of $38.5 million a year earlier, and Adjusted EBITDA of $13.1 million, up from $1.7 million. Revenue growth was broad-based, including Canada, a tenth consecutive record quarter in Israel under the PEACE NATURALS® brand, and strong demand in Germany and other markets. Cronos ended the quarter with $827.0 million in cash, short-term investments and interest-bearing deposits and had repurchased 12.3 million shares in the first half of 2026, reducing shares outstanding to about 370.7 million. The company is prepared to close its pending acquisition of CanAdelaar B.V. in the Netherlands, while also facing a new Israeli anti-dumping investigation that could affect medical cannabis imports into that market.